title: Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
abstract: OBJECTIVE
  To evaluate the antitumor efficacy of a vascular targeting strategy that combines an agent that disrupts established tumor blood vessels (ZD6126) with one that interferes with new vessel formation (ZD6474) in models of human renal cell carcinoma (Caki-1) and Kaposi's sarcoma (KSY-1).
  
  
  METHODS
  Caki-1 and KSY-1 xenograft-bearing nude mice were treated with ZD6126 and ZD6474 either as single agents or in combination when the tumors reached a size of approximately 200 mm(3). ZD6126 therapy consisted of three doses of 100 mg/kg administered 1, 3, and 5 days after the tumor reached the starting size. ZD6474 was administered daily (25 mg/kg) on Days 1-5. In the combination studies, ZD6474 treatment began immediately after the first dose of ZD6126. The tumor response to treatment was evaluated using a regrowth delay endpoint.
  
  
  RESULTS
  Significant tumor growth delays were observed in both tumor models with either agent with the treatment regimen used. In the Caki-1 and KSY-1 models, respectively, ZD6126 treatment resulted in a tumor growth delay of 23 and 26 days and ZD6474 produced a tumor growth delay of 24.5 and 14.5 days. When ZD6126 and ZD6474 were combined, the tumor growth delays increased to 55 (Caki-1) and 86 (KSY-1) days. In the KSY-1 model, the combination therapy also resulted in 3 of 8 long-term tumor-free survivors.
  
  
  CONCLUSIONS
  These results indicate that statistically significant antitumor efficacy can be achieved using a treatment strategy that combines a therapy that targets the established tumor blood vessels with one that interferes with the process of angiogenesis.
authors.affiliation: Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL, USA. siemadw@ufl.edu
authors.forename: Dietmar W
authors.initials: DW
authors.lastname: Siemann
authors.forename: Wenyin
authors.initials: W
authors.lastname: Shi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002292:Carcinoma, Renal Cell / Q000098:blood supply; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D010880:Piperidines / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D012514:Sarcoma, Kaposi / Q000098:blood supply
chemical_list: D020533:Angiogenesis Inhibitors; C455219:N-acetylcochinol-O-phosphate; D009943:Organophosphorus Compounds; D010880:Piperidines; D011799:Quinazolines; C452423:vandetanib